Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

NORWOOD, Mass. , Oct. 14, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced a poster presentation at the SITC 2022 Annual Meeting being held November 8-12, 2022.

Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

NORWOOD, Mass., Sept. 26, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors.

Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

CRB-913 is a novel oral cannabinoid type 1 receptor (CB1) inverse agonist with potent pre-clinical anti-obesity activity CRB-913 markedly enhances pre-clinical efficacy of liraglutide, semaglutide, and tirzepatide CB1 inverse agonism is a clinically validated therapeutic approach to treating obesity NORWOOD, Mass. , Sept. 22, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that preclinical data for CRB-913 are being presented today in an oral presentation at the European Association for the Study of Diabetes 2022 Annual Conference taking place in Stockholm, Sweden.

Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference

NORWOOD, Mass. , Sept. 12, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D.

Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -16.67% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates

Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on track for mid-2023 Expanding immuno-oncology pipeline through strategic transactions remains key priority Cash and investments on hand of $74 million funds operations into the first quarter of 2024 NORWOOD, Mass. , Aug. 9, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.

Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CRB-601 is a highly potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of TGF b in the local tumor microenvironment Additional non-clinical data demonstrates combination benefit across a diverse range of syngeneic models with differential sensitivity to checkpoint inhibition Anti-tumor activity correlates with increases in proliferating CD4+ and CD8+ T-cells as well as the NK cell population and a shift towards M1 macrophage polarization, supporting the hypothesis the CRB-601 may overcome immune cell exclusion NORWOOD, Mass. , May 11, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that new preclinical data for CRB-601 are being presented today in an oral presentation at the New York Academy of Sciences (NYAS) Frontiers in Cancer Immunotherapy Conference in New York, NY.

Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates

Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on-track for the first half of 2023 Expanding immuno-oncology pipeline through strategic transactions remains key priority Cash and investments on hand of $86.8 million funds operations into the first quarter of 2024 NORWOOD, Mass. , May 10, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.

Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

NORWOOD, Mass. , April 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CRB-601 are being presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting being held from April 8-13, 2022, in New Orleans, LA.

Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting

Greenlane Holdings

HEXO Corp

SNDL Inc.

Marijuana penny stocks to watch right now. The post Hot Marijuana Penny Stocks Under $1 To Watch Ahead Of MORE Act Vote appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Marijuana Penny Stocks Under $1 To Watch Ahead Of MORE Act Vote

NORWOOD, Mass., March 11, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that  Yuval Cohen, Ph.D.

Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

NORWOOD, Mass., March 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the fourth quarter and year-end of 2021.

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates

The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 31.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corbus Pharmaceuticals (CRBP)

NORWOOD, Mass., Dec. 7, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") today announced the appointment of Rachael Brake, Ph.D.

Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

NORWOOD, Mass., Nov. 12, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the third quarter of 2021.

Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

NORWOOD, Mass., Nov. 11, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced that Yuval Cohen, Ph.D.

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 71.15% year over year to ($0.15), which missed the estimate of ($0.12).

Recap: Corbus Pharmaceuticals Q2 Earnings

Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided corporate updates and reported financial results for the second quarter of 2021.

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Arbutus Biopharma

Aerpio Pharmaceuticals Inc

Digital Brands Group Inc

9F Inc - ADR

NovaBay Pharmaceuticals

NexGen Energy

Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist

AFC Gamma

Arena Pharmaceuticals

Canopy Growth

Evogene

India Globalization Capital

OrganiGram Holdings Inc.

Tilray Brands

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials

Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, today announced topline results from the Phase 3 D ETER M INE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis.

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

News for Corbus Pharmaceuticals Holdings Stock (CRBP)